Johnson & Johnson stock (US4781601046): oncology trial update and analyst focus at the start of June

Johnson & Johnson shares on the New York Stock Exchange were in the spotlight at the start of the week after the US healthcare group reported updated Phase 2 data showing a 42% response rate for an investigational therapy in advanced head and neck cancer, underscoring the strategic role of oncology in its growth story, according to MarketScreener citing MT Newswires as of 06/01/2026.

The stock last closed at USD 225.33 on NYSE on 05/29/2026, with intraday data on 06/01/2026 around USD 222.65 implying a move of roughly -1.2% on the day as investors digested the trial update and broader sector moves, according to MarketScreener as of 06/01/2026.

The trial results form part of Johnson & Johnson's push to expand its oncology franchise, which the company highlights as a core pillar of its strategy to "eliminate cancer," as stated on its oncology overview page, according to Johnson & Johnson as of 06/01/2026.

For German investors, Johnson & Johnson is also available via secondary listings such as Tradegate in EUR, providing an additional access point alongside the primary NYSE listing in the United States, according to Tradegate data cited by MarketScreener as of 06/01/2026.

As of: 01/06/2026

By the editorial team - specialized in equity coverage.

Johnson & Johnson: core business model

Johnson & Johnson focuses on innovative medicines and medical technology solutions, with revenue primarily generated from prescription drugs and devices across oncology, immunology, cardiovascular and surgical care, according to Johnson & Johnson as of 06/01/2026.

What banks and research houses say about Johnson & Johnson

Analyst attention on Johnson & Johnson remains steady as the group advances its oncology programs and prepares for its next reporting dates, with consensus data from MarketBeat as of 05/30/2026 indicating a broadly positive stance on the NYSE-listed stock.

According to MarketBeat as of 05/30/2026, the consensus across analysts covering Johnson & Johnson points to an overall favorable rating profile and an average price target of about USD 252.87, compared with a recent close of USD 225.33, based on MarketBeat data as of 05/30/2026.

Conclusion

The fresh Phase 2 data in advanced head and neck cancer keeps Johnson & Johnson's oncology ambitions in focus at the beginning of June, while the share price on the NYSE reflects both stock-specific news and broader healthcare sentiment. The current analyst consensus and average price target underline that Wall Street continues to follow the US group closely as it develops its pipeline and heads toward upcoming catalysts such as future clinical readouts and earnings dates.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.